Literature DB >> 16154354

Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs.

C Spina1, V Tangpricha, M Yao, W Zhou, M M Wolfe, H Maehr, M Uskokovic, L Adorini, M F Holick.   

Abstract

It has been recognized that people who live at higher latitudes and who are vitamin D deficient are at higher risk of dying from many common cancers including colon cancer. To evaluate the role of vitamin D deficiency on colon tumor growth, Balb/c adult male mice were fed either a vitamin D sufficient or vitamin D deficient diet for 10 weeks. Mice were arranged into groups of six and each animal received subcutaneously 10(4) MC-26 cells in the posterior trunk. The tumor size was recorded daily. By day 9 there was a significant difference in tumor volume between the vitamin D sufficient and vitamin D deficient mice. By day 18 the vitamin D deficient animals had a tumor size that was 56% larger compared to the animals that were vitamin D sufficient. To determine whether treatment with active vitamin D analogs could further decrease colon tumor growth in a vitamin D sufficient state, groups of mice were treated with the novel 19-nor-Gemini compounds. The mice were fed a low calcium diet. Twenty-four hours after tumor implantation, the mice received, three times weekly, one of the vitamin D analogs or the vehicle. The group that received Gemini 1,25-dihydroxy-21(3-hydroxy-3-trifluoromethyl-4-trifluoro-butynyl)-19-nor-20S-cholecalciferol (3) showed a dose-dependent decrease in tumor volume. On day 19, at the dose level of 0.02microg molar equivalents (E), the tumor volume was reduced by 41% when compared to the control group. At the same time point, the hexadeuterated analog 1,25-dihydroxy-21(3-hydroxy-3-trifluoromethyl-4-trifluoro-butynyl)-26,27-hexadeutero-19-nor-20S-cholecalciferol (4), administered at the 10-fold lower dose of 0.002microgE, showed a 52% reduction in tumor volume (p<0.05), compared to the control group. Animals that received 1,25(OH)(2)D(3) at 0.002 and 0.02microg showed a trend in tumor volume reduction at the highest dose but the changes were not statistically significant. An evaluation of serum calcium concentrations revealed that the calcium levels were normal in all groups, except the group receiving 0.02microgE of 4. The results from these studies demonstrate that vitamin D deficiency may accelerate colon cancer growth and that novel Gemini analogs of 1,25(OH)(2)D(3) may be an effective new approach for colon cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16154354     DOI: 10.1016/j.jsbmb.2005.06.003

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  12 in total

1.  Emerging role of vitamin D in colorectal cancer.

Authors:  Wonmo Kang; Sujin Lee; Eunyi Jeon; Ye-Rang Yun; Kook-Hyun Kim; Jun-Hyeog Jang
Journal:  World J Gastrointest Oncol       Date:  2011-08-15

2.  Importance of apical membrane delivery of 1,25-dihydroxyvitamin D3 to vitamin D-responsive gene expression in the colon.

Authors:  Nicholas J Koszewski; Ronald L Horst; Jesse P Goff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-07-26       Impact factor: 4.052

Review 3.  Resurrection of vitamin D deficiency and rickets.

Authors:  Michael F Holick
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

4.  Therapeutic Efficacy of Vitamin D in Experimental c-MET-β-Catenin-Driven Hepatocellular Cancer.

Authors:  Akiko Matsuda; Kaori Ishiguro; Irene K Yan; Tushar Patel
Journal:  Gene Expr       Date:  2018-08-29

5.  Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling.

Authors:  Hong Jin Lee; Jae-Young So; Andrew DeCastro; Amanda Smolarek; Shiby Paul; Hubert Maehr; Milan Uskokovic; Nanjoo Suh
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-19       Impact factor: 4.292

Review 6.  Natural compounds as anticancer agents: Experimental evidence.

Authors:  Jiao Wang; Yang-Fu Jiang
Journal:  World J Exp Med       Date:  2012-06-20

7.  Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity.

Authors:  Hong Jin Lee; Shiby Paul; Nadi Atalla; Paul E Thomas; Xinjie Lin; Ill Yang; Brian Buckley; Gang Lu; Xi Zheng; You-Rong Lou; Allan H Conney; Hubert Maehr; Luciano Adorini; Milan Uskokovic; Nanjoo Suh
Journal:  Cancer Prev Res (Phila)       Date:  2008-11

8.  Novel Gemini vitamin D(3) analogs have potent antitumor activity.

Authors:  Tsuyako Saito; Ryoko Okamoto; Talin Haritunians; James O'Kelly; Milan Uskokovic; Hubert Maehr; Stanislaw Marczak; Pawel Jankowski; Riem Badr; H Phillip Koeffler
Journal:  J Steroid Biochem Mol Biol       Date:  2008-09-30       Impact factor: 4.292

9.  Calcitriol derivatives with two different side chains at C-20. V. Potent inhibitors of mammary carcinogenesis and inducers of leukemia differentiation.

Authors:  Hubert Maehr; Hong Jin Lee; Bradford Perry; Nanjoo Suh; Milan R Uskokovic
Journal:  J Med Chem       Date:  2009-09-10       Impact factor: 7.446

10.  Vitamin D3 enhances the tumouricidal effects of 5-Fluorouracil through multipathway mechanisms in azoxymethane rat model of colon cancer.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Osama Adnan Kensara; Amr Mohamed Mohamed; Shakir Idris; Jawwad Ahmad; Athar Khojah
Journal:  J Exp Clin Cancer Res       Date:  2015-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.